Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENRAPRED Study
2024-514843-27-00Phase 4Completed
- Sponsor
- CHU de Nantes
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of benralizumab in severe asthma, sponsored by CHU de Nantes. Primary endpoint: Early blood gene-expression signature of benralizumab response. Started Oct 2021; status: completed.
02
Drugs
benralizumab
03
Conditions
severe asthma
Beyond the preview
Go deeper on 2024-514843-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514843-27-00.